Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Nordea Investment Management AB grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.4% in the ...

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $85 from $98 and keeps a Buy rating on the shares.

ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

High-rolling investors have positioned themselves bullish on CRISPR Therapeutics CRSP, and it's important for retail traders to take note. \This activity came to our attention today through ...